ARTICLE | Company News
GPC Biotech, Aventis deal
December 18, 2000 8:00 AM UTC
GPC will use its PathCode protein interaction mapping technology to identify and validate proteins that interact with an AVE target. Separately, the companies are identifying and validating targets in...